Status:
RECRUITING
Biomarkers for Diagnostic, Prognostic and of Response to Treatment in Adult Langerhans Cell Histiocytosis
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Histiocytosis, Langerhans-Cell
Eligibility:
All Genders
18+ years
Brief Summary
Adult Langerhans histiocytosis (LCH) is a rare disease of unknown etiology, characterized by the activation of the MAPK (Mitogen-activated protein kinases) pathway, driven by various somatic mutations...
Eligibility Criteria
Inclusion
- LCH patients :
- Age ≥ 18 years
- All confirmed LCH seen at the reference center whatever the clinical presentation
- Controls :
- Age ≥ 18 years
- Patients with diffuse lung cystic disease, pulmonary emphysema and healthy smokers
- All :
- Signing an informed consent
- Patients with health insurance
Exclusion
- Persons under guardianship or curatorship, or deprived of freedom by a judicial or administrative decision.
- People benefiting from Medical Aid from the State (AME)
- Pregnant women, parturient and mothers who are breastfeeding.
- Persons subject to psychiatric care and persons admitted to a health or social establishment for purposes other than research
- Persons unable to express their consent
Key Trial Info
Start Date :
March 25 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 25 2034
Estimated Enrollment :
570 Patients enrolled
Trial Details
Trial ID
NCT06197204
Start Date
March 25 2024
End Date
March 25 2034
Last Update
July 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Saint Louis
Paris, France